LONDON (ShareCast) - (Sharecast News) - Wound care-focussed predictive artificial intelligence (AI) developer Spectral MD announced the start of its clinical validation study to support its diabetic foot ulcer (DFU) application for the 'DeepView' wound imaging system.
The AIM-traded firm said its proprietary technology combines multi-spectral imaging and AI to provide clinicians with an "immediate healing assessment" for DFU, allowing them to provide a "more accurate and timely" diagnosis for therapeutic intervention.

It said the study would collect data from up to 200 adult subjects across seven potential clinical sites, to further develop DeepView's AI algorithm.

Patient enrolment for the validation study began this month, and was expected to complete in November.

"We are very pleased to have initiated the Clinical Validation Study, the next critical step towards the completion of development for the DFU application for DeepView Wound Imaging System," said the company's vice-president of clinical affairs, Mary Regan.

"To obtain robust clinical data, the Spectral MD team has selected leading wound care providers to advance and develop our DeepView wound imaging technology."

At 1121 BST, shares in Spectral MD Holdings were down 4.23% at 34p.

Reporting by Josh White at Sharecast.com.

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE